Oruka Therapeutics (ORKA) Short-term Investments (2016 - 2026)

Oruka Therapeutics has reported Short-term Investments for 5 years, with the latest figure at $339.3 million in Q1 2026.

• For the quarter ending Q1 2026, Short-term Investments rose 27.79% year-over-year to $339.3 million; the trailing twelve-month figure through Mar 2026 stood at $339.3 million (up 27.79% YoY), and the FY2025 full-year result was $290.1 million, down 7.63% from the prior year.
• Short-term Investments for Q1 2026 stood at $339.3 million, up from $290.1 million in the prior quarter.
• The five-year high for Short-term Investments was $339.3 million in Q1 2026, with the low at $257.9 million in Q3 2025.
• Average Short-term Investments over 3 years is $288.3 million, with a median of $277.8 million recorded in 2025.
• Year-over-year, Short-term Investments retreated 7.63% in 2025 and gained 27.79% in 2026.
• Tracing ORKA's Short-term Investments over 3 years: stood at $314.1 million in 2024, then declined by 7.63% to $290.1 million in 2025, then grew by 16.96% to $339.3 million in 2026.
• The last three Short-term Investments figures came in at $339.3 million (Q1 2026), $290.1 million (Q4 2025), and $257.9 million (Q3 2025), per Business Quant data.

Peer Comparison